INTRODUCTION {#s1}
============

Pancreatic cancer (PC) is one of the most malignant cancers which usually discovered late and has a poor prognosis \[[@R1]\]. Although the resection rate of pancreatic cancer has improved in recent years, postoperative pancreatic fistula, bleeding and other complications are still more, and often because tumor invasion, surrounding blood vessels bile duct resection and other important pipeline structure due to limited resection range. Therefore, systemic palliative chemotherapy (such as gemcitabine) is often used, however, the sensitivity of pancreatic cancer to chemotherapy is poor, and the prognosis is still poor \[[@R2]--[@R4]\]. Approximately 40% of patients present with locally advanced pancreatic cancer (LAPC), the estimated rates of 1- and 5-year survival of LAPC are 24% and 4.3%, respectively \[[@R5]\]. Therefore, identifying more effective therapies for patients with unresectable PC remains an important clinical challenge.

Aimed at unresectable PC, the traditional ablation method such as cryoablation, which has been used and showed a good effect assuredly but also damaged the peripheral blood vessels, bile ducts and pancreatic ducts and other important structures easily \[[@R6], [@R7]\]. The incidence of postoperative hemorrhage and pancreatic fistula was high, and peripheral tumor ablation is not complete \[[@R8]\]. However, Irreversible electroporation (IRE) is an emerging, non-thermal, image-guided tumor ablation technique that has been proven feasible and safe for treating locally advanced pancreatic tumors \[[@R9]--[@R12]\]. IRE is a newly developed method that causes apoptosis without injuring the structural components of tissues. Fuda Cancer Hospital (Guangzhou, China) has been conducting a prospective study of percutaneous IRE ablation of advanced pancreatic cancer (APC) earliest since approved by CFDA. However, as the vast majority of patients with APC patients have distal metastasis, and IRE technology can only treat primary tumors, tumor cells can reach any tissue or organ via the hematogenous spread.

Some previous reports have demonstrated that cancer development and progression in APC patients are associated with the tumor immune \[[@R13]--[@R18]\]. Immunotherapy benefit in APC patients has been studied for many years \[[@R19]--[@R21]\]. However, due to the expression of MHC down-regulated, tumor cells often appeared immune escape \[[@R22]\]. As we all known, NK cells play an important role against foreign matter earliest including cancer \[[@R23], [@R24]\]. With understanding NK function, NK cell transfer has promised anti-tumor effects on various tumors \[[@R25]--[@R29]\], including pancreatic cancer \[[@R30]--[@R34]\].

In this study, we prospectively investigated the clinical response of IRE combined with NK cell immunotherapy in patients with unresectable (Stage III/ IV) pancreatic cancer to provide a potential therapeutic pattern.

RESULTS {#s2}
=======

Patient demographics and related data during IRE {#s2_1}
------------------------------------------------

Pre-treatment information was collected from the 71 patients, who were from China (*n* = 35), Indonesia (*n* = 7), Malaysia (*n* = 14), the Middle East (*n* = 9) and other countries (*n* = 6), with a median age of 57.0 years (range, 41--73 years). Among them, adenocarcinoma was detected in 46 patients. 49 of the 71 patients had the previously received chemotherapy (Gemcitabine, *n* = 34; FOLFIRINOX, *n* = 15), with a median of four cycles (range, 2 to 6 cycles). Patients underwent a 105.1 ± 32.4 (39\~202) minute surgical procedure and 9.3 ± 4.9 (3\~21) ablation cycle. According to the seventh edition of the American Joint Committee on Cancer (AJCC), the data of the two groups were compared, and the patient demographics were not statistically different (Table [1](#T1){ref-type="table"}). The related operative data of the patients receiving IRE showed that anesthesia was smooth, the electrocardiogram (ECG) monitor displayed myocardial contractions within the absolute refractory period, and the patient vital signs were stable (Table [2](#T2){ref-type="table"}).

###### Patient demographics

  Patient characteristics pre-treatment   Stage III (*n* = 32)   Stage IV (*n* = 39)   *P* value
  --------------------------------------- ---------------------- --------------------- -------------
  **Sex (male/female)**                   17/15                  19/20                 *P* = 0.764
  **Median age (y)**                      55                     59                    *P* = 0.788
  **Pathology**                                                                        *P* = 0.869
  Adenocarcinoma                          23                     26                    
  **Tumor location**                                                                   *P* = 0.911
  Head and neck                           23                     26                    
  Body and tail                           6                      5                     
  **Tumor size before IRE**               5.01 ± 1.06            4.92 ± 1.38           *P* = 0.864
  **Karnofsky performance status**                                                     *P* = 0.587
  70                                      13                     19                    
  80                                      14                     16                    
  90                                      5                      4                     
  **Chemotherapy**                        29                     37                    *P* = 0.564

###### Related operative data of patients receiving IRE (*n* = 67, mean ± standard deviation)

  Intraoperative data                 X ± S            Range
  ----------------------------------- ---------------- ----------------
  **Ablation duration (min)**         105.1 ± 32.4     39.0--202.0
  **Perioperative bleeding (mL)**     152.0 ± 45.0     90.0--230.0
  **Electrode needle spacing (cm)**   1.8 ± 0.3        1.5--2.5
  **Ablation times /(time)**          9.3 ± 4.9        3.0--23.0
  **Average voltage (V)**             2635.0 ± 165.2   2400.0--3000.0
  **Average pulse width (μs)**        78.9 ± 6.4       70.0--90.0

Safety evaluation {#s2_2}
-----------------

Throughout the trial, adverse events of all patients were limited to grades 1 and 2, included local (mainly tussis 13.4%, nausea and emesis 7.1%, pain of puncture point 29.6% and duodenum and gastric retention 4.3%) and systemic (mainly fatigue 22.3%, fever 31.6%, and transient reduction of intraoperative blood pressure 25.1% and white cell count reduction 18.3%) reactions, fever was the most frequent (Table [3](#T3){ref-type="table"}). Symptomatic treatment relieved all symptoms within the day and the symptoms did not reappear. There was no pancreatic fistula, bleeding, bile leakage, or abdominal cavity infection at 2 months post-treatment.

###### Adverse events for all patients

  Adverse events                                         Case (*n*)   Percentage (%)   Grade
  ------------------------------------------------------ ------------ ---------------- -------
  **Local reactions**                                                                  
  Tussis                                                 10           13.4             1
  Nausea and emesis                                      5            7.1              1
  Pain of puncture point                                 21           29.6             1
  Duodenum and gastric retention                         3            4.3              2
  **Systemic reactions**                                                               
  Fatigue                                                16           22.3             1
  Fever                                                  22           31.6             1
  Transient reduction of intraoperative blood pressure   18           25.1             2
  White cell count reduction                             13           18.3             2

The serum amylase levels of all patients at 1 day pre-treatment were normal (0\~220 U/L). Compared with pre-IRE, there was no significant increase in amylase levels at 1 day after IRE and 7 day after IRE (*P* \> 0.05, Figure [1](#F1){ref-type="fig"}).

![Error bar chart shows amylase values before and after IRE\
Compared with pre-IRE, there was no significant increase in amylase levels at 1 day after IRE and 7 day after IRE (*P* \> 0.05).](oncotarget-08-101795-g001){#F1}

Clinical efficacy {#s2_3}
-----------------

The pre-treatment immune test data of were merged and compared with post-treatment (Table [4](#T4){ref-type="table"}). For lymphocyte count, all subsets were significantly higher in the IRE-NK group post-treatment, especially NK (*P* \< 0.001); for lymphocyte function, Th1 cytokine levels were higher in the IRE-NK group, while Th2 cytokine levels were essentially unchanged.

###### Comparison of lymphocyte number and function

                         Stage III                        Stage IV                                                                 
  ---------------------- ------------ ------------------- -------------------- ---------------------- ------------ --------------- ------------------
  **Number (cell/μL)**                                                         **Number (cell/μL)**                                
  **Total T cell**       1329 ± 54    1578 ± 69^\*^       1900 ± 72^\*\*^      **Total T cell**       1258 ± 49    1287 ± 57^\*^   1456 ± 94^\*^
  **CD8 + T cell**       614 ± 12     709 ± 37^\*^        778 ± 15^\*^         **CD8 + T cell**       614 ± 11     632 ± 26        745 ± 15^\*^
  **CD4 + T cell**       726 ± 31     808 ± 35^\*^        861 ± 33^\*\*^       **CD4 + T cell**       735 ± 30     766 ± 35        802 ± 36
  **NK cell**            409 ± 38     456 ± 61            658 ± 73^\*\*\*^     **NK cell**            389 ± 37     392 ± 46        569 ± 69^\*\*\*^
  **B cell**             309 ± 11     465 ± 33^\*\*^      551 ± 41^\*^         **B cell**             334 ± 10     365 ± 33        351 ± 38
  **Function (pg/mL)**                                                         **Function (pg/mL)**                                
  **IL-2**               9.1 ± 3.3    16.9 ± 3.9^\*\*^    23.1 ± 4.6^\*\*\*^   **IL-2**               9.9 ± 3.1    10.6 ± 3.5      17.1 ± 4.8^\*\*^
  **TNF-β**              3.6 ± 2.4    9.4 ± 2.1^\*\*\*^   14.6 ± 2.8^\*\*\*^   **TNF-β**              3.8 ± 2.1    9.8 ± 2.2       13.7 ± 2.6^\*\*^
  **IFN-γ**              3.9 ± 3.1    11.1 ± 2.6^\*\*^    15.2 ± 3.8^\*\*\*^   **IFN-γ**              4.8 ± 2.8    10.9 ± 3.1      13.1 ± 29^\*^
  **IL-4**               10.2 ± 2.1   10.1 ± 3.4          11.2 ± 3.1           **IL-4**               9.7 ± 2.3    10.5 ± 2.4      10.2 ± 3.7
  **IL-6**               13.3 ± 3.9   15.1 ± 4.5          15.5 ± 5.9^\*\*^     **IL-6**               11.2 ± 3.2   12.2 ± 3.7      12.6 ± 3.9
  **IL-10**              9.4 ± 2.7    9.7 ± 2.3           10.3 ± 3.2           **IL-10**              8.9 ± 3.1    9.3 ± 2.6       12.1 ± 3.1

Every cell subset or cytokine was analyzed by Dunnett\'s multiple comparison test (one-way analysis of variance). NK cell, natural killer cell; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; ^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001.

CA19--9 value of all patients were higher than normal at 1 day pre-treatment and decreased gradually at day 1, 7, and 1 month post-treatment in the two groups, but still higher than normal (Figure [2](#F2){ref-type="fig"}). There was no difference between IRE and IRE-NK group at day 1, and 7 post-treatment (*P* \> 0.05), but at 1 month post-treatment, CA19--9 expression was lower in the IRE-NK than in the IRE (*P* \< 0.05).

![Change of CA 19--9\
There was no difference between IRE and IRE-NK group at day 1, and 7 post-treatment (*P* \> 0.05), but at 1 month post-treatment, CA19--9 expression was lower in the IRE-NK than in the IRE (*P* \< 0.05).](oncotarget-08-101795-g002){#F2}

The clinical response was observed at 2 months post-treatment (Table [5](#T5){ref-type="table"}). In stage III group, the RR in IRE-NK (66.7%) was higher than in IRE (47.1%, *P* \< 0.05), but no difference on DCR (*P* \> 0.05); In stage IV, the DCR in IRE-NK (70.6%) was higher than in IRE (59.1%, *P* \< 0.05), but no difference on RR (*P* \> 0.05). Representative results from two patients who received IRE-NK therapy were shown in Figure [3](#F3){ref-type="fig"}.

###### Clinical response

            Total   Stage III   *P*-value   Total         Stage IV   *P*-value          
  --------- ------- ----------- ----------- ------------- ---------- ----------- ------ -------------
  Number    32      17          15          *P* \> 0.05   39         22          17     *P* \> 0.05
  CR        7       3           4           *P* \> 0.05   0          0           0      *P* \> 0.05
  PR        11      5           6           *P* \> 0.05   13         8           5      *P* \> 0.05
  SD        7       5           2           *P* \> 0.05   12         5           7      *P* \> 0.05
  PD        7       4           3           *P* \> 0.05   14         9           5      *P* \> 0.05
  RR (%)    56.3    47.1        66.7        *P* \< 0.05   33.3       36.4        29.4   *P* \> 0.05
  DCR (%)   78.1    76.5        80.0        *P* \> 0.05   64.1       59.1        70.6   *P* \< 0.05

Clinical responses were evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RR, response rate; DCR, disease control rate.

![CT scans taken before, during and after IRE-NK therapy\
Patient 1: (**A**--**C**) (Female patient, 70 years old, T4N1M0, stage III): A. Pre-IRE CT showed a compressed duodenum and encased common bile duct and pancreatic duct due to the tumor, which was 3.1 × 2.2 cm (red arrow) in dimension; B. during IRE, two electrodes were inserted and the distance between them was 2.0 cm, as shown in this CT image; C. three month post-IRE-NK, CT showed no enhancement in the occupying lesion, with mild shrinkage of the area. Patient 2: (**D**--**F**) (Male patient, 59 years old, T4N1M1, stage IV): D. A contrast-enhanced CT scan taken before IRE showed a 5.7 × 4.2 cm contrast-enhanced lesion (red arrow) in the neck and body of the pancreas; (E) Two IRE electrodes were inserted into the tumor; F. CT scan taken two months after IRE-NK showed a 5.7 × 4.0 cm lesion with a large area of necrosis in the neck and body of the pancreas. Patient 3: (**G-I)** (male patient, 51 years old, T4NxM0, stage III): G. pancreatic head carcinoma, tumor size was about 4.1 × 3.5 cm (red arrow) and performed IRE ablation; H. 2 months after IRE, the tumor was reduced to 3.3 × 2.4 cm; I. 3 months after IRE, the tumor was reduced to 2.4 × 1.8 cm.](oncotarget-08-101795-g003){#F3}

Follow-up {#s2_4}
---------

After a median follow-up of 7.4 months (3.6 --11.2 months): in stage III group, median PFS after IRE was higher in IRE-NK (9.3 months) than in IRE (8.1 months, *P* = 0.0465, Figure [4A](#F4){ref-type="fig"}), median OS after IRE was higher in IRE-NK (13.2 months) than in IRE (11.4 months, *P* = 0.0411, Figure [4B](#F4){ref-type="fig"}), and median PFS after IRE who received multiple NK was higher than who just received single NK (9.8 months vs.8.1 months, *P* = 0.0423, respectively, Figure [5A](#F5){ref-type="fig"}), similarly, median OS after IRE who received multiple NK was higher than who received single NK (13.9 months vs.12.3 months, *P* = 0.0524, respectively, Figure [5B](#F5){ref-type="fig"}); in stage IV group, there was no difference of median PFS between IRE and IRE-NK (5.0 months vs.5.3 months, *P* \> 0.05, respectively, Figure [4C](#F4){ref-type="fig"}), but median OS was higher in IRE-NK (9.8 months) than in IRE (8.7 months, *P* = 0.0397, Figure [4D](#F4){ref-type="fig"}), and median PFS and OS who received multiple NK were a little more than just received single NK, but they were both no difference (both *P* \> 0.05, Figure [5C, 5D](#F5){ref-type="fig"}).

![Correlation of median PFS and OS with type of treatment\
(**A**) Comparison of median PFS between 17 patients who underwent IRE and 15 patients who underwent IRE-NK in stage III group; (**B**) Comparison of median OS between 17 patients who underwent IRE and 15 patients who underwent IRE-NK in stage III group; (**C**) Comparison of median PFS between 22 patients who underwent IRE and 17 patients who underwent IRE-NK in stage IV group; (**D**) Comparison of median OS between 22 patients who underwent IRE and 17 patients who underwent IRE-NK in stage IV group.](oncotarget-08-101795-g004){#F4}

![Correlation between median PFS and OS with courses of NK\
(**A**) Comparison of median PFS between 8 patients who underwent single NK and 7 patients who underwent multiple NK in stage III group; (**B**) Comparison of median OS between 8 patients who underwent single NK and 7 patients who underwent multiple NK in stage III group; (**C**) Comparison of median PFS between 9 patients who underwent single NK and 8 patients who underwent multiple NK in stage IV group; (**D**) Comparison of median OS between 9 patients who underwent single NK and 8 patients who underwent multiple NK in stage IV group.](oncotarget-08-101795-g005){#F5}

DISCUSSION {#s3}
==========

For the majority of patients with advanced PC, tumor is not suitable to resect. The best options for metastatic patients are chemotherapy, radiofrequency ablation, and other palliative therapies, but the median survival time was only 6--11 months \[[@R35], [@R36]\]. IRE is a feasible and safe technique for PC ablation and \[[@R37], [@R38]\] has the potential to preserve the adjacent tissues, such as the nerves, vessels, and bile duct. Fuda Cancer Hospital (Guangzhou, China) has been conducting a prospective study of percutaneous IRE ablation of local advanced pancreatic cancer (LAPC) earliest by Dr. Niu which also validated its safety and efficacy \[[@R39]\].

In previous studies, the researchers were limited to IRE ablation of pancreatic cancer with stage III \[[@R37], [@R40], [@R41]\], Martin RG, et al propose that as long as the patient has not developed metastatic disease and the maximum axial diameter is not above 4.0 cm after induction therapy, then we would recommend proceeding with IRE therapy. However, in our study, we performed IRE in patients with stage III/IV PC, and the mean diameter of tumor \> 4 cm, CT revealed no injury to the pancreatic duct, bile duct, or surrounding intestinal lumen post-treatment. The main results of our study indicate that IRE treatment has clinical significance for \> 5cm tumors for patients with stage III pancreatic cancer and for patients with stage IV pancreatic cancer within the criteria for a limited metastatic tumor. This finding is in different to previously published inclusion criteria. Scheffer HJ, et al. \[[@R41]\] retrospectively examined the efficacy of IRE for locally advanced pancreatic cancer (stage III) and reported PFS and OS was 8 months and 11 months, respectively, in our study, the mean tumor diameter of 5.01 ± 1.06 cm patients with stage III pancreatic cancer who had a better median OS (12.2 months) and the same PFS (8.1 months). But there was no exactly report about how IRE effected the median PFS and OS of stage IV PC so far, we exhibited them firstly (5.0 months and 9.1 months, respectively). However, due to the vast majority of advanced PC patients have been confirmed the existence of the distal metastasis, IRE only treat primary tumors or metastases, possible role limited for advanced PC cell metastasis.

It is increasingly clear that cancer occurence and development in HCC patients are affected by tumor immune \[[@R42], [@R43]\], indicating that immune-based therapy could be an effective treatment option for patients with LAPC. Our previous research of Cryo-DC/CIK treatment with in metastatic PC \[[@R44]\] and HCC \[[@R45]\] has displayed a good clinical outcome. Suffered from cryotherapy, vast antigen released continuously, which stimulated the immune system, but CIK could not kill the tumor cell directly, so we brought in NK cells by understanding NK function. In our study, we attempted to investigate the safety and clinical efficacy of percutaneous IRE combined with allogeneic natural killer cell therapy for treating unresectable PC, then the median PFS, OS, RR and DCR were assessed. To our surprise was that allogeneic NK cells combined with IRE for unresectable PC exhibited a synergistic effect, significantly enhanced the immune function of patients (Table [4](#T4){ref-type="table"}), the increasing number of NK cells after allogeneic NK cells immunotherapy may be related to ectogenic NK cells amplified *in vivo*, because NK cells were infused in the period of logarithmic phase which owned the best activity and amplified sequentially, hence, the patients who received NK therapy could increase the number of NK cells *in vivo*, and enhancing immune function. Most of all the median PFS and OS of stage III group were both higher in IRE-NK than who just received IRE, and multiple NK infusion showed a better median PFS and OS than single NK; the same to stage IV, the median OS was higher in IRE-NK than who underwent only IRE, but multiple NK infusion was no effect to median PFS and OS. And we found that the patients who underwent IRE-NK had a better RR in stage III and higher DCR in stage IV. Facts proved that this comprehensive therapy was also safety and efficacy.

For decades, natural killer (NK) NK cells existed as "non-specific" killer cells were different from CTL or other immunocytes identified the target. We have learned that NK cells are trained to recognize "non-self" histocompatibility antigens (human leukocyte antigen, HLA) on the surface of cells through their killer cell immunoglobulin-like (KIR) receptors. Recent discoveries that better explain how NK cells recognize and kill their targets and their ability to produce immune-active cytokines have made them more attractive tools for immunotherapy. In view of this, we brought NK cells into this clinical research. In our previous report \[[@R46]\], showed a good outcome for allogenic NK cell immunotherapy to advanced renal cell cancer Therefore, we used allogeneic NK cell adoptive therapy in this study. Facts proved that it was tolerant and efficacy. But whether the current number and purity of NK cells would be the optimal dose or not which is worthy us considering, maybe, we will carry out the dose grope in the future.

In conclusion, in this single-center, prospective study, we provided evidence that allogeneic NK cell therapy combined with percutaneous IRE has better median PFS and OS for patients with unresectable PC, which provides a potential therapeutic pattern.

MATERIALS AND METHODS {#s4}
=====================

Ethics {#s4_1}
------

This clinical research was approved by the Guangzhou Fuda Cancer Hospital ethics committee. In accordance with the Declaration of Helsinki, written informed consent was obtained from each participant.

Patients {#s4_2}
--------

This was a prospective study of the therapeutic effects of the combined treatment for patients with unresectable (Stage III/IV) pancreatic cancer enrolled between July 2016 and May 2017. We enrolled 71 patients using the following criteria: (1) expected survival \> 3 months; (2) age 30--80 years; (3) Karnofsky performance status (KPS) \> 60; (4) platelets ≥ 80 × 10^9^/L, white blood cells ≥ 3 × 10^9^/L, neutrophils ≥ 2 × 10^9^/L, hemoglobin ≥ 90 g/L, prothrombin time--international normalized ratio (0.8--1.5), adequate hepatic function (bilirubin \< 20 μM, aminotransferase \< 60 U/L) and renal function (serum creatinine \< 130 μM, serum urea \< 10 mM); (5) APC confirmed by pathology and/or imaging; (6) stage IV patients were limited to metastatic tumors \<4 and the maximum diameter of metastatic tumors \< 4 cm; (7) absence of level 3 hypertension, severe coronary disease, myelosuppression, respiratory disease, acute or chronic infection, and autoimmune diseases. The patients were divided into stage III (32 patients, 17 patients received only IRE and 15 patients received IRE-NK: 8 patients underwent a course of NK and 7 patients underwent ≥ 3 courses ) and stage IV (39 patients, 22 patients received only IRE and 17 patients received IRE-NK: 9 patients underwent a course of NK and 8 patients underwent ≥ 3 courses, Figure [6A](#F6){ref-type="fig"}).

![(**A**) Consort diagram. The patients were divided into stage III (32 patients, 17 patients received only IRE and 15 patients received IRE-NK: 8 patients underwent a course of NK and 7 patients underwent ≥ 3 courses) and stage IV (39 patients, 22 patients received only IRE and 17 patients received IRE-NK: 9 patients underwent a course of NK and 8 patients underwent ≥ 3 courses); (**B**) Procedure of IRE-NK therapy. All enrolled patient\'s kinsfolk were informed and peripheral blood collected for NK at 7days before IRE, IRE carried out at day 9, and at day 12, NK cell completed culture and infused intravenously at d 13\~15.](oncotarget-08-101795-g006){#F6}

IRE procedure {#s4_3}
-------------

All patients underwent neuromuscular blockade and general anesthesia. Computed tomography (CT) and ultrasound were used to guide electrode insertion, and IRE was synchronized to deliver electrical pulses coordinating with the cardiac rhythm. The distance between the electrodes was 1.5--2.0 cm. One or more pullbacks were performed if the target region was \> 2 cm in diameter. After the ablation, the patient was transferred to the intensive care unit for overnight observation, and then transferred to the general ward after no acute complications were confirmed. Relevant treatment was administered if there were any complications. Two surgeons (L.Z.N. and L.Z.) with 4--8 years of experience in image-guided tumor ablation performed all procedures.

CT examination {#s4_4}
--------------

The patients were required to undergo plain CT and enhanced CT at 1 week pre-treatment, and followed at 1 month and 2 or 3 months post-treatment. The maximum diameter was measured and compared pre-treatment and post-treatment.

NK cell therapy {#s4_5}
---------------

For NK cells culture, after isolated PBMC from whole blood, using the Human HANK Cell *In Vitro* Preparation Kit (Hank Bioengineering Co., Ltd, Shenzhen, China), including the lethally radiated K562-mb15--41BBL (K562D2) stimulatory cells \[[@R47]\], plasma treatment fluid, lymphocyte culture fluid additives, serum-free medium additives and cell infusion additives. It is dedicated for the expansion and activation of NK cells in peripheral blood or umbilical cord blood mononuclear cells *in vitro*, the preparation of NK cells with higher quantity, purity and activity, namely HANK cells \[[@R48]\]. The final cell count and quality control inspection were performed at day 9 of culture, and the qualified indicators included proportion of living cells ≥ 90%, proportion of CD56 + CD3- cells ≥ 85% (detection by flowcytometry was shown previously \[[@R48]\]), endotoxin content ≤ 1 EU/ml, cell viability ≥ 80% (K562 cells were used as target cells, cytotoxicity assay was shown previously \[[@R48]\]), Bacteria, fungi and mycoplasma culture negative.

80 ml peripheral blood from allogenic donors was drawn 7 days before IRE and the immunotherapy was given 3 days after IRE. Approximately 8--10 billion HANK cells may be harvested after culture from 80 ml of peripheral blood. After 12 days of cell culture, the NK cells were divided into three groups and intravenously infused into the patients from Day 13 to 15. All cell preparation processes were performed by the same technician and assessed by another technician. Each patient must two cycles NK therapy continuously as a course.

For donor selection, the killer cell immunoglobulin-like receptors (KIRs) genotyping should be mismatched to the human leukocyte antigen (HLA) class I molecules of the patient \[[@R48]--[@R52]\]. We used PCR-SSP to detect the KIR/HLA-Cw which can get the result on the day.

IRE-NK therapy {#s4_6}
--------------

At 7 days before IRE, the relatives of the enrolled patients were informed and their peripheral blood was collected to obtain the NK cells. IRE was carried out on day 9, and on day 12, the NK cell culture was completed, and the cells were infused intravenously on day 13--15 (Figure [6B](#F6){ref-type="fig"}). Each patient was required to accept two continuous cycles as a course of NK after IRE.

Safety evaluation index {#s4_7}
-----------------------

Adverse events and complications: Adverse events during treatment and post-treatment, and immediate post-treatment complications, were closely observed and recorded.

The patient serum amylase index was checked pre-IRE and on day 1, 3, and 7 post-IRE to determine whether there was pancreatitis.

Curative effect evaluation index {#s4_8}
--------------------------------

Detection of immune function: 2 mL peripheral blood was drawn to detect immune function and was assessed using flow cytometry (FACSCanto™ II; BD, Grand Island, NY, USA). The tested indices included lymphocyte number and function in the patients' peripheral blood. BD multitest 6-color TBNK reagent (no. 644611) was used to detect the number of CD3^+^CD4^+^ cells (95% range: 441--2156/μL), CD3^+^CD8^+^ cells (95% range: 125--1312/μL), total CD3^+^ cells (95% range: 603--2990/μL), CD3^-^CD19^+^ cells (95% range: 107--698/μL), and CD3^-^CD16^+^CD56^+^ cells (95% range: 95--640/μL). BD Cytometric Bead Array Human Th1/Th2 Cytokine Kit II (no. 551809) was used to detect the expression levels of interleukin-2 (IL-2; 95% range: 8--12.5 pg/mL), IL-4 (95% range: 3.5--6 pg/mL), IL-6 (95% range: 2.7--8.5 pg/mL), IL-10 (95% range: 1.8--4 pg/mL), tumor necrosis factor (TNF; 95% range: 1.7--2.5 pg/mL), and interferon-γ (IFN-γ; 95% range: 1.5--4 pg/mL). The tests were performed according to the protocols in the instruction manuals. Results above or within the reference range were defined as normal immune function; one or more results below the reference range were defined as immune dysfunction. Peripheral blood drawn was 1 day before IRE and 3 days after IRE or IRE-NK.

Carbohydrate antigen 19--9 (CA19--9) expression was tested pre-treatment and at day 1, 7, and 1 month post-treatment.

Imaging changes: The World Health Organization published the tumor curative effect evaluation standard as a main study objective for observing tumor change \[[@R53]\]. Based on the degree of change of the largest transverse diameter, the therapeutic effect of the two treatments was divided into complete response (CR), arterial enhancement imaging of all target lesions disappeared; partial response (PR), the diameter sum reduction of target lesions was \> 30%; stable disease (SD), tumor regression failed to achieve PR or tumor progression did not develop progressive disease (PD); and PD, the diameter sum progression of tumor was \> 20%. To accurately observe the effect, we compared the sum area of all tumors before and after treatment. The recent curative effect must have been maintained at \> 4 weeks; CR + PR denoted the effective rate (RR).

Follow-up: The patients were required to undergo plain CT and enhanced CT at 1 week pre-treatment, and followed at 1 month and 2 months post-treatment. The endpoints of interest were progression-free survival (PFS) and overall survival (OS). PFS was defined as the interval between IRE and local relapse, distant metastasis, or death, whichever occurred first. OS was calculated as the interval between the date of IRE and the date of death from any cause. All patients after treatment are focused by our manual and intelligent follow-up system persistently.

Evaluation and statistical analysis {#s4_9}
-----------------------------------

Complications were recorded and classified in accordance with the Common Terminology Criteria of Adverse Events v4.0 \[[@R54]\]. Radiographic local tumor control was assessed using image-guided tumor ablation criteria \[[@R55]\]. The basic characteristics of the two groups were compared using the chi-square test; immunity detection result data are presented as the mean ± standard deviation; the changes of imaging were compared using the Student\'s *t*-test; local and systemic adverse events were marked in the nursing records; the median PFS and OS was analyzed by Kaplan--Meier statistical method and using the log-rank test to compare. Significant differences were indicated by *P* \< 0.05, *P* \< 0.01 or *P* \< 0.001. All analyses were conducted using GraphPad software (GraphPad, San Diego, CA, USA).
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